GET DAILY SIGNALSPACS Group (PACS) Reports Q3 Revenue of $1.50 Billion, Up 11.5%, and Raises Full-Year Guidance
Key Takeaways
- PACS Group reported total revenue of approximately $1.50 billion for the third quarter of 2026, up roughly 11.5% year over year and ahead of the consensus estimate of about $1.46 billion.
- Net income attributable to PACS Group rose about 16% year over year to $60.8 million, with reported diluted earnings per share (EPS) of $0.37, up from $0.32 a year earlier.
- Management raised its full-year 2026 revenue guidance to a range of $5.95 billion to $6.05 billion, reflecting confidence in its acquisition-driven growth strategy.
- The company continued scaling quickly, completing acquisitions of operations at 32 Florida facilities on October 1 and 11 Texas facilities by November 1.
- Same-store skilled nursing facility revenue grew 6.4% year over year, with same-store occupancy improving to 91.3% from 89.3%.
Why This Quarter’s Results Matter
PACS Group stands among the largest post-acute care operators in the United States, and its growth has centered on acquiring skilled nursing and senior care facilities then improving their performance. This third-quarter update provides a useful check on whether rapid portfolio expansion can continue without eroding margins. Recent quarters have shown double-digit revenue increases and better occupancy, paired with raised guidance. Still, higher general and administrative costs from expansion and the integration of new sites remain key items to monitor. The results also arrive against a backdrop of ongoing attention to reimbursement trends and quality metrics across the post-acute care industry.
The Reported Figures
For the three months ended September 30, 2026, PACS Group posted total revenue of approximately $1.50 billion, an 11.5% increase from $1.34 billion in the same period a year earlier. Patient and resident service revenue reached $1.498 billion, beating the consensus estimate of roughly $1.46 billion.
Net income attributable to the company climbed about 16% to $60.8 million from $52.4 million. Diluted EPS came in at $0.37 versus $0.32 previously. Operating income rose to $99.7 million from $86.3 million. On a GAAP basis, EPS fell short of the consensus range of about $0.55 to $0.57, largely because of higher general and administrative expenses of $138.4 million (up from $102.5 million) and increased depreciation tied to the larger facility base.
Over the first nine months of 2026, revenue totaled approximately $4.35 billion and net income attributable to PACS Group reached $217.9 million. Management updated full-year 2026 revenue guidance to $5.95 billion–$6.05 billion.
Market Reaction and Analyst Views
Before the release, all six covering analysts rated the stock a buy, with a consensus price target near $59. Estimates had eased modestly over the prior two months. The revenue beat and raised guidance should support investor confidence in top-line momentum and acquisition execution. At the same time, the rise in general and administrative costs and the GAAP EPS miss versus consensus may lead some to weigh near-term integration expenses against longer-term scale benefits. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Investors Should Watch Next
Attention now turns to the pace of integration for the 32 Florida facilities acquired on October 1 and the 11 Texas sites added by November 1. Integration costs have weighed on margins, so the speed at which general and administrative expenses stabilize relative to revenue will be an important indicator. Same-store occupancy reached 91.3%, and same-store skilled nursing revenue rose 6.4%, pointing to healthy underlying demand. Maintaining these trends across a broader, more diverse portfolio will be telling. Clinical quality remains relevant as well, with 250 facilities—about 78.9% of the total—holding four- or five-star CMS ratings. Reimbursement trends and any updates on state quality-incentive programs could also shape results. Management’s commentary on the earnings call should offer more color on margin outlook, the acquisition pipeline, and how the updated guidance reflects recent deals.
Using AI Tools in Portfolio Review
When analyzing names like PACS Group, I often turn to Tickeron’s AI-powered tools to scan for comparable setups and emerging signals across the healthcare sector. The platform’s customizable filters help surface patterns and ideas more efficiently than manual work alone, which supports a more informed view of relative performance and potential opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PACS's Stochastic Oscillator slumps oversold zone
The Stochastic Oscillator for PACS moved into oversold territory on November 03, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
PACS moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PACS crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +3.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACS advanced for three days, in 105 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 98 of 121 cases where PACS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for PACS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PACS as a result. In 29 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for PACS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In 13 of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
PACS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PACS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.656) is normal, around the industry mean (204.016). P/E Ratio (27.140) is within average values for comparable stocks, (19.314). Projected Growth (PEG Ratio) (1.085) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.094) among similar stocks. P/S Ratio (1.209) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement